NCT04971226 2026-04-06
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Novartis
Phase 3 Active not recruiting
Clinical Trials
19 trialsNCT05456191 2026-02-06
ASC4START
Novartis
Phase 3 Active not recruiting
NCT02627677 2021-11-26
OPTIC-2L
Takeda
Phase 3 Terminated
NCT01743989 2021-07-15
ENESTPath
Novartis
Phase 3 Completed
NCT00471497 2020-11-18
ENESTnd
Novartis
Phase 3 Completed
NCT02115386 2019-12-10
MACS1532
Novartis
Phase 3 Terminated
NCT02272777 2019-08-19
A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase
Novartis
Phase 3 Completed
NCT03079505 2019-01-23
DANIN
Hamad Medical Corporation
Phase 3 Terminated
NCT02108951 2017-10-27
ENESTswift
Novartis
Phase 3 Terminated
NCT01126892 2017-02-28
ENACT
Novartis
Phase 3 Completed
NCT01289028 2017-01-02
Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.
Novartis
Phase 3 Completed
NCT00760877 2016-11-08
Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)
Novartis
Phase 3 Completed
NCT00785785 2016-06-16
ENESTg1
Novartis
Phase 3 Completed
NCT01275196 2016-04-08
Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients
Novartis
Phase 3 Completed
NCT01254188 2016-03-03
ENESTxtnd
Novartis
Phase 3 Completed
NCT00802841 2015-11-16
LASOR
Novartis
Phase 3 Completed
NCT00751036 2014-03-26
MACS0375
Novartis
Phase 3 Terminated
NCT00471328 2012-06-12
ENEST
Novartis
Phase 3 Completed
NCT00519090 2011-11-07
ENEST
Novartis
Phase 3 Terminated